Although GrB in cancer tissues is widely used as activation marker for cytotoxic lymphocytes, and lymphocyte-derived GrB-positive tumor immunostaining is associated with a favorable clinical outcome in a large spectrum of cancers, in some cases, GrB expression in tumors correlates to the severity of the disease, poor prognosis and therapy resistance (91–96). This evidence concerns the gene GZMB and neoplasm.